Tags : Samsung


Insights+ Key Biosimilars Events of November 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients. Hence, the providers are more likely to adopt biosimilars as a “reference […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (Jun 15-19, 2020)

 1.  Ultragenyx and Kyowa Kirin’s Crysvita (burosumab) Receive the US FDA’s Approval for the Treatment of Tumor-Induced Osteomalacia  Published: Jun 19, 2020 | Tags: Ultragenyx, Kyowa Kirin, Crysvita, burosumab, Receives, US, FDA, Approval, Treatment, Tumor-Induced Osteomalacia 2.  Pfizer and Sangamo’s Giroctocogene Fitelparvovec (SB-525) Demonstrate Positive Effect in P-I/II Alta Study for Hemophilia A Published: Jun 18, 2020 […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (April 06 -10, 2020)

Amgen Signs a Partnership with Adaptive Biotechnologies to Develop for COVID-19 Published: Apr 09, 2020 | Tags: Amgen, Adaptive Biotechnologies, Develop, Abs, COVID-19 2.  Samsung Biologics Signs an Agreement with Vir Biotechnology to Develop Abs for COVID-19 Published: Apr 09, 2020 | Tags: Samsung Biologics, Agreement, Vir Biotechnology, Abs, COVID-19 3.  Abbott’s TriClip Transcatheter Tricuspid […]Read More